Department of Medicine and Therapeutics, Chinese University of Hong Kong.
Prince of Wales Hospital, Sha Tin, Hong Kong.
Curr Opin Pulm Med. 2018 Jul;24(4):367-373. doi: 10.1097/MCP.0000000000000487.
Pleural infection remains an important pulmonary disease, causing significant morbidity and mortality. There is a resurgence of disease burden despite introduction of antibiotics and pneumococcal vaccines. A revisit of the pathogenesis and update on intervention may improve the care of pleural infection.
Recent studies have uncovered the prognostic implication of the presence of a pleural effusion in patients with pneumonia. Identifying where the bacteria lives may have diagnostic and therapeutic implications. Over-exaggerated pleural inflammation may underlie development of parapneumonic effusion as indirect evidence and a randomized study in children raised a role of corticosteroids in parapneumonic pleural effusions, but data are lacking for adults. Optimization of the delivery regimen of intrapleural fibrinolytic and deoxyribonuclease therapy is ongoing.
The review aims to review the current practice and explore new directions of treatment on pleural infection.
胸膜感染仍然是一种重要的肺部疾病,导致发病率和死亡率显著增加。尽管抗生素和肺炎球菌疫苗已经问世,但疾病负担仍在重现。重新审视发病机制并更新干预措施可能会改善胸膜感染的治疗效果。
最近的研究揭示了肺炎患者胸腔积液存在的预后意义。确定细菌的生存位置可能具有诊断和治疗意义。过度夸大的胸膜炎症可能是导致类肺炎性胸腔积液的间接证据,一项针对儿童的随机研究提出了在类肺炎性胸腔积液中使用皮质类固醇的作用,但成人的数据尚缺乏。目前正在优化胸腔内纤维蛋白溶解和脱氧核糖核酸酶治疗的给药方案。
本综述旨在回顾胸膜感染的当前治疗实践,并探讨新的治疗方向。